No connection

Search Results

SPRY vs TLRY

SPRY
ARS Pharmaceuticals, Inc.
BEARISH
Price
$8.18
Market Cap
$812.3M
Sector
Healthcare
AI Confidence
85%
TLRY
Tilray Brands, Inc.
BEARISH
Price
$7.15
Market Cap
$833.3M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
SPRY
--
TLRY
--
Forward P/E
SPRY
-10.8
TLRY
26.37
P/B Ratio
SPRY
7.11
TLRY
2.37
P/S Ratio
SPRY
9.64
TLRY
0.97
EV/EBITDA
SPRY
-4.13
TLRY
175.52

Profitability

Gross Margin
SPRY
60.13%
TLRY
27.68%
Operating Margin
SPRY
-147.63%
TLRY
-52.7%
Profit Margin
SPRY
-203.25%
TLRY
-156.67%
ROE
SPRY
-92.33%
TLRY
-63.16%
ROA
SPRY
-33.05%
TLRY
-1.47%

Growth

Revenue Growth
SPRY
-67.6%
TLRY
-7.8%
Earnings Growth
SPRY
--
TLRY
--

Financial Health

Debt/Equity
SPRY
1.47
TLRY
0.64
Current Ratio
SPRY
7.28
TLRY
2.79
Quick Ratio
SPRY
6.93
TLRY
1.31

Dividends

Dividend Yield
SPRY
--
TLRY
--
Payout Ratio
SPRY
0.0%
TLRY
0.0%

AI Verdict

SPRY BEARISH

SPRY exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. Despite a strong liquidity position (Current Ratio 7.28), the company is facing a catastrophic revenue collapse of -67.60% YoY and deep negative profit margins of -203.25%. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual data, which shows bearish insider selling and a 0/100 technical trend. The valuation remains speculative and disconnected from current operational performance.

Strengths
Very high current ratio (7.28) providing a short-term liquidity cushion
Strong quick ratio (6.93) indicating minimal reliance on inventory for liquidity
Positive gross margin (60.13%) suggesting a viable core product price point
Risks
Severe revenue contraction (-67.60% YoY)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Deeply negative profitability (Profit Margin -203.25%)
TLRY BEARISH

Tilray Brands exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a company in financial distress. The firm suffers from catastrophic profitability metrics, including a profit margin of -156.66% and a total failure to beat earnings estimates in the last four quarters (0/4). While a strong current ratio of 2.79 provides a temporary liquidity buffer, the long-term trajectory is characterized by massive value destruction, with a 5-year price decline of 95.8%. The disconnect between the 'Buy' analyst consensus and the deterministic health scores suggests the stock is being traded on speculative regulatory hopes rather than operational performance.

Strengths
Strong short-term liquidity with a Current Ratio of 2.79
Low Price-to-Sales ratio (0.97) suggesting revenue is not overvalued
Manageable Debt/Equity ratio of 0.64
Risks
Extreme negative profit margins (-156.66%) and ROE (-63.16%)
Consistent earnings misses with an average surprise of -76.47% over the last 4 quarters
Negative Year-over-Year revenue growth (-7.80%)

Compare Another Pair

SPRY vs TLRY: Head-to-Head Comparison

This page compares ARS Pharmaceuticals, Inc. (SPRY) and Tilray Brands, Inc. (TLRY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile